2026 年至 2032 年射频消融设备市场（按产品类型、应用和地区）

射频消融设备市场评估（2026-2032）

射频消融技术的进步正在推动市场成长。这些技术创新使治疗更加可靠、可靠且易于获取，同时提高了准确性、有效性和安全性。因此，射频消融技术的进步将呈指数级增长，推动市场规模在2024年超过47.4亿美元，到2032年达到100.8亿美元的估值。

由于门诊手术便捷、经济高效且住院时间短，越来越受到人们的偏好。射频消融设备顺应了这个趋势，它提供微创手术，恢復时间极短，对患者和医疗服务提供者来说都是一个相当吸引人的选择。因此，预计门诊病人手术的日益普及将推动市场在2026年至2032年间以10.90%的复合年增长率成长。

射频消融设备市场定义/概述

射频消融术 (RFA) 设备是一种专用医疗设备，利用高频电流产生可控热量，并作用于特定组织或神经，从而诱导凝固或破坏。这种微创手术广泛应用于介入放射学、疼痛管理、肿瘤学、心臟病学和皮肤病学等多个医学领域。 RFA 因其能够精准定位患处而不损伤周围组织而备受推崇，使其成为多种疾病的安全有效治疗选择。

RFA 通常用于治疗慢性疼痛，例如下背痛或关节痛，以及控制某些类型的癌症、心律不整、静脉曲张、良性和恶性肿瘤等引起的疼痛。在疼痛管理中，RFA 透过阻断神经讯号提供持久的缓解，并在肿瘤学和心臟病学中用于消融肿瘤和异常的心臟组织。

射频消融术 (RFA) 设备的持续技术进步旨在改善其设计、增强其能量传输系统并提高手术效率。这些创新正在提高治疗精准度、缩短恢復时间并扩大射频消融 (RFA) 可治疗的疾病范围。研究也致力于扩展射频消融术 (RFA) 的应用范围，以治疗新的疾病并改善治疗通讯协定，使射频消融术 (RFA) 成为现代医疗干预的重要工具。

人口老化和慢性病负担的增加将如何推动射频消融设备市场的成长？

全球人口老化和慢性病数量的增加正在推动射频消融市场的成长。根据世界卫生组织预测，2050年，全球60岁以上人口将达到21亿人。美国疾病管制与预防中心报告称，截至2022年，85%的老年人至少患有一种慢性病，60%的老年人将患有两种或两种以上的慢性病。由于老年人口的成长，2020年至2022年间，医疗保险在射频消融治疗上的支出增加了32%。

美国) 报告称，2021 年将新增 190 万例癌症病例，其中肝癌病例年增长率为 2.5%。根据 GLOBOCAN 2022 报告，射频消融 (RFA) 疗法在早期肝癌治疗中约占 25%。 RFA 在小肝细胞癌病例中的临床成功率据称高达 97%。美国心臟协会 (美国 Heart Association) 报告称，2022 年将进行超过 45 万例心导管电气烧灼术手术，较 2020 年增长 15%。联邦医疗保险 (Medicare) 数据显示，2020 年至 2023 年间，心臟射频消融手术的报销申请将增加 28%。

美国食品药物管理局（FDA）在2021年至2023年间核准了八种新型射频消融术（RFA）设备。介入放射学会（ISRA）报告称，2022年新型RFA系统将手术时间缩短了40%。 2020年至2023年，医院采用先进RFA系统的比例增加了35%。 《美国管理式医疗杂誌》（American Journal of Managed Care）报告称，2022年RFA比传统手术费用降低45%。根据2023年医疗保健成本与利用计画（HCUP）的数据，平均住院时间从5.2天（手术）减少到1.3天（RFA）。保险理赔数据显示，RFA的总治疗费用比传统手术低30%。

有限的熟练医护人员如何阻碍射频消融设备市场的成长？

美国麻醉师协会 ( 美国 Society of Anesthesiologists) 报告称，2022 年，经过培训的射频消融 (RFA) 专家短缺率将达到 22%。美国医学院协会 (Association of 美国 Medical Colleges) 的数据显示，截至 2023 年，只有 35% 的介入放射科医师将接受高阶射频消融 (RFA) 技术培训。从 2020 年到 2022 年，RFA 手术的训练成本将上涨 45%，这将限制小型医疗中心的采用（介入放射学会 (Society of Intervention Radiology)）。 2023 年，一台 RFA 机器的平均成本将达到 8.5 万至 17.5 万美元。根据美国医疗保险和医疗补助服务中心 (CMS) 的数据，医疗保险报销仅能涵盖手术总费用的 60% 至 70%。

由于预算限制，2022 年医院对 RFA 设备的投资下降了 18%。

美国食品药物管理局 (FDA) 报告称，2020 年至 2022 年间，与射频消融术 (RFA) 手术相关的不利事件报告增加了 15%。临床研究发现，心臟射频消融术 (RFA) 手术的併发症发生率为 4.7%（美国心臟协会，2023 年）。复杂性肿瘤消融病例的技术失败率为 8.3%（《介入放射学期刊》，2022 年）。 2022 年，FDA 对新型射频消融设备的核准时间平均为 18 个月，而其他医疗设备的核准时间平均为 12 个月。 2020 年至 2023 年间，监管合规成本增加了 28%（医疗设备製造商协会）。

目录

第一章 引言

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章 市场概述

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

第五章射频消融设备市场（依产品类型）

• 概述
• 可重复使用的
• 一次性的
• 资本设备

第六章射频消融设备市场（按应用）

• 概述
• 心臟病学和心律管理
• 妇科
• 疼痛管理
• 外科肿瘤学
• 肿瘤学

7. 射频消融设备市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

第八章 竞争态势

• 概述
• 各公司市场排名
• 主要发展策略

第九章 公司简介

• Hologic, Inc.
• Medtronic
• AngioDynamics, Inc.
• Boston Scientific Corporation
• St. Jude Medical, Inc.
• Halyard Health, Inc.
• Stryker, CR Bard, Inc.
• AtriCure, Inc.
• Johnson & Johnson
• BIOTRONIK Schweiz AG

第十章 重大进展

• 产品发布/开发
• 合併与收购
• 业务扩展
• 伙伴关係与合作

第十一章 附录

• 相关调查

Radiofrequency Ablation Devices Market Valuation - 2026-2032

Advancements in radiofrequency ablation technology are fueling market growth. These innovations have enhanced the precision, efficacy, and safety of treatments, making them more reliable and accessible. Thus, advancements in radiofrequency ablation technology surge the growth of market size surpassing USD 4.74 Billion in 2024 to reach a valuation of USD 10.08 Billion by 2032.

The growing preference for outpatient procedures is driven by their convenience, cost-effectiveness, and shorter hospital stays. Radiofrequency ablation devices, being minimally invasive, align with this trend by offering procedures that require minimal recovery time, making them an attractive option for both patients and healthcare providers. Thus, the increasing popularity of outpatient procedures enables the market to grow at a CAGR of 10.90% from 2026 to 2032.

Radiofrequency Ablation Devices Market: Definition/ Overview

Radiofrequency ablation (RFA) devices are specialized medical instruments that utilize high-frequency electrical currents to generate controlled heat, which is applied to specific tissues or nerves to induce coagulation or destruction. This minimally invasive procedure is widely used across various medical disciplines, including interventional radiology, pain management, oncology, cardiology, and dermatology. RFA is particularly valued for its ability to precisely target affected areas without damaging surrounding tissues, making it a safe and effective treatment option for several conditions.

Common applications of RFA include the treatment of chronic pain conditions, such as back pain and joint pain, as well as the management of specific types of cancer, cardiac arrhythmias, varicose veins, and both benign and malignant tumors. In pain management, RFA offers long-lasting relief by disrupting nerve signals, while in oncology and cardiology, it is used to ablate tumors or aberrant heart tissue.

Ongoing technological advancements in RFA devices aim to improve their design, enhance energy delivery systems, and increase procedural efficiency. These innovations are enhancing treatment precision, reducing recovery times, and expanding the range of conditions that can be treated with RFA. Research is also focused on broadening the applications of RFA to target new medical conditions and refine treatment protocols, positioning RFA as a crucial tool in modern medical interventions.

How does the Growing Geriatric Population & Chronic Disease Burden Surge the Growth of the Radiofrequency Ablation Devices Market?

An increasing aging population and rising chronic disorders globally propel the growth of the radiofrequency ablation devices market. According to the WHO, the global population aged 60+ will reach 2.1 billion by 2050 The CDC reported that 85% of older adults have at least one chronic condition, with 60% having two or more as of 2022. Medicare spending on RF ablation procedures increased by 32% between 2020-2022 due to rising elderly population demands

The National Cancer Institute reported 1.9 million new cancer cases in 2021, with liver cancer cases increasing by 2.5% annually. According to GLOBOCAN 2022, RF ablation was used in approximately 25% of early-stage liver cancer treatments. Clinical success rates of 97% were reported for RF ablation in small hepatocellular carcinoma cases. The American Heart Association reported 450,000+ cardiac ablation procedures in 2022, a 15% increase from 2020. Medicare data showed a 28% increase in reimbursement claims for cardiac RF ablation procedures between 2020-2023

FDA approved 8 new RF ablation devices between 2021-2023. The Society of Interventional Radiology reported a 40% reduction in procedure time with newer RF ablation systems in 2022. Hospital adoption of advanced RF ablation systems increased by 35% from 2020 to 2023. The American Journal of Managed Care reported 45% lower costs for RF ablation compared to traditional surgery in 2022. Average hospital stay reduced from 5.2 days (surgery) to 1.3 days (RF ablation) according to the Healthcare Cost and Utilization Project (HCUP) 2023. Insurance claims data showed 30% lower total treatment costs with RF ablation versus conventional surgery.

How do Limited Skilled Healthcare Professionals Impede the Growth of the Radiofrequency Ablation Devices Market?

The American Society of Anesthesiologists reported a 22% shortage of trained RF ablation specialists in 2022. According to the Association of American Medical Colleges, only 35% of interventional radiologists are trained in advanced RF ablation techniques as of 2023. Training costs for RF ablation procedures increased by 45% from 2020 to 2022, limiting adoption in smaller healthcare facilities (Society of Interventional Radiology). The average cost of RF ablation equipment ranges from $85,000 to $175,000 as of 2023. Medicare reimbursement covers only 60-70% of the total procedure cost, according to CMS data 2022

Hospital investment in RF ablation equipment decreased by 18% in 2022 due to budget constraints.

The FDA reported a 15% increase in adverse event reports related to RF ablation procedures from 2020 to 2022. Clinical studies showed complication rates of 4.7% for cardiac RF ablation procedures (American Heart Association, 2023). Technical failure rates of 8.3% were reported in complex tumor ablation cases (Journal of Interventional Radiology, 2022). FDA approval time for new RF ablation devices averaged 18 months in 2022, compared to 12 months for another medical devices. Regulatory compliance costs increased by 28% between 2020-2023 (Medical Device Manufacturers Association).

Category-Wise Acumens

How the Advanced Technology in Disposable RFA Devices Surge the Growth of Disposable Equipment Segment?

The disposable equipment segment dominates the radiofrequency ablation (RFA) devices market, driven by the efficiency and safety of medical procedures. The advanced technology integrated into disposable RFA devices enables the creation of large areas of coagulative necrosis in a controlled and precise manner. These devices are relatively low in toxicity, reducing the likelihood of adverse side effects and minimizing the risk of complications, which further fuels their adoption across various medical specialties.

Disposable RFA devices have a reduced risk of cross-contamination. By using fresh, sterile equipment for each patient, the likelihood of infection or contamination is significantly lowered, enhancing patient safety and boosting confidence in treatment outcomes. Additionally, continuous technological advancements, such as improved electrode designs and the use of advanced materials, are further propelling the growth of this segment, as they enhance the precision, effectiveness, and ease of use of disposable RFA devices.

How does the Increasing Adoption of Effective Treatment for Cancerous Cells Accelerate the Growth of the Oncology Segment?

The oncology segment stands out as dominant in the radiofrequency ablation devices market, driven by its growing adoption as an effective treatment for cancerous cells, particularly in high-risk patients with unresectable or refractory tumors. RFA is increasingly used in surgical oncology to treat various types of cancer, offering a minimally invasive alternative to conventional surgery. Its ability to precisely target cancerous tissues while minimizing damage to surrounding healthy cells has made it a preferred option for addressing both primary and metastatic tumors. This is especially beneficial for patients with multiple tumors or those who cannot undergo open surgery, significantly improving their survival outcomes and overall quality of life.

The rising global prevalence of cancer is a major factor fueling the growth of this segment. As cancer cases increase, so does the demand for advanced, less invasive treatment options like RFA. The technology's ability to reduce potential side effects, shorten recovery times, and deliver precise results has made it a valuable tool in oncology. Moreover, continuous advancements in RFA technology, such as enhanced imaging guidance and the development of multi-electrode systems, have further boosted its efficacy in treating tumors.

Country/Region-wise Acumens

How does the Advanced Healthcare Infrastructure & High Healthcare Spending Accelerate the Growth of the Radiofrequency Ablation Devices Market in North America?

North America substantially dominates the radiofrequency ablation devices market driven by the advanced healthcare infrastructure and high healthcare investment. U.S. healthcare spending reached USD 4.3 Trillion in 2022, with 12% allocated to medical devices and technologies. The number of ambulatory surgery centers performing RF ablation in North America increased by 32% from 2020 to 2023. Canada's healthcare spending on minimally invasive procedures grew by 25% between 2020-2022, with RF ablation accounting for 18% of this growth.

The American Cancer Society reported 1.9 million new cancer cases in 2022, with liver cancer cases increasing 2.8% annually. According to the CDC, cardiovascular diseases affected 48% of adults over 20 in 2022, with 850,000+ requiring interventional procedures. The Heart Rhythm Society documented that atrial fibrillation affects 5.5 million Americans, with RF ablation procedures increasing by 38% from 2020 to 2023

Medicare expanded RF ablation procedure coverage by 35% between 2020-2023, covering 85% of total procedure costs. Private insurance claims for RF ablation procedures increased by 42% from 2020 to 2022. The average reimbursement rate for RF ablation procedures in the U.S. increased from $5,200 in 2020 to $6,800 in 2023.

How does the Rapidly Growing Geriatric Population & Disease Burden Escalate the Growth of the Radiofrequency Ablation Devices Market in the Asia Pacific?

Asia Pacific is anticipated to witness the fastest growth in the radiofrequency ablation devices market during the forecast period owing to the rising aging population and increasing diseases. According to WHO Western Pacific Region, the 65+ population in Asia Pacific reached 300 million in 2022, with an annual growth rate of 3.5%. China reported a 45% increase in liver cancer cases from 2020-2022, with RF ablation being used in 30% of early-stage treatments. Japan's Ministry of Health reported that 42% of its population will be over 60 by 2023, leading to a 28% increase in RF ablation procedures since 2020.

India's healthcare budget increased by 37% in 2022, with 15% allocated to advanced medical technologies including RF ablation (Indian Ministry of Health). South Korea's government provided USD 2.8 Billion in healthcare technology subsidies from 2020-2023, boosting RF ablation device adoption by 42%. Japan's Ministry of Health approved 28% more reimbursement for RF ablation procedures in 2022 compared to 2020, increasing accessibility.

Competitive Landscape

The Radiofrequency Ablation Devices Market is a dynamic and competitive landscape, driven by the increasing adoption of minimally invasive procedures. Key players in this market are continuously innovating to develop advanced RFA systems and accessories.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the radiofrequency ablation devices market include:

• Hologic, Inc.
• Medtronic
• AngioDynamics, Inc.
• Boston Scientific Corporation
• Jude Medical, Inc.
• Halyard Health, Inc.
• Stryker, C. R. Bard, Inc.
• AtriCure, Inc.
• Johnson & Johnson
• BIOTRONIK Schweiz AG

Latest Developments:

• In April 2022, AtriCure announced the EnCompass Clamp, a component of its Isolator Synergy ablation system, which provides parallel closure, uniform pressure, and tailored power via synergy radiofrequency, hence improving the efficiency of cardiac tissue ablation during cardiac surgery.
• In April 2022, Royal Philips announced the launch of the KODEX-EPD system, which improves imaging and mapping capabilities for RF ablation and includes the Tissue Engagement Viewer as well as support for the Medtronic DiamondTemp system.

Radiofrequency Ablation Devices Market, By Category

• Product Type:
• Disposable Equipment
• Capital Equipment
• Reusable Equipment
• Application:
• Oncology
• Cardiology and Cardiac Rhythm
• Management
• Gynecology
• Pain Management
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL RADIOFREQUENCY ABLATION DEVICES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL RADIOFREQUENCY ABLATION DEVICES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL RADIOFREQUENCY ABLATION DEVICES MARKET, BY PRODUCT TYPE

• 5.1 Overview
• 5.2 Reusable Equipment
• 5.3 Disposable Equipment
• 5.4 Capital Equipment

6 GLOBAL RADIOFREQUENCY ABLATION DEVICES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Cardiology & Cardiac Rhythm Management
• 6.3 Gynecology
• 6.4 Pain Management
• 6.5 Surgical Oncology
• 6.6 Oncology

7 GLOBAL RADIOFREQUENCY ABLATION DEVICES MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL RADIOFREQUENCY ABLATION DEVICES MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Hologic, Inc.
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Medtronic
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 AngioDynamics, Inc.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Boston Scientific Corporation
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 St. Jude Medical, Inc.
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Halyard Health, Inc.
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Stryker, C. R. Bard, Inc.
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 AtriCure, Inc.
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Johnson & Johnson
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 BIOTRONIK Schweiz AG
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research